Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (August 2021)
33 slides from Curis's investor presentation, August 2021
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: CRIS
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”
Slide 3: Corporate Overview
Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $161M as of June 30, 2021; cash runway into 2024 CA-4948: first-in-class inhi
Slide 4: Pipeline
Pipeline Curis develops novel, first-in-class cancer drugs PRE-CLINICAL CLINICAL MARKETED Dose Clinical Indication Proof of Principle Safety Optimization Activity Pivotal Commercial Two programs Heme Malignancies are the focus of this presentation CA-4948* IRAK4-driven Lymphoma IRAK4 (NHL, CLL, WM)
Slide 5: IRAK4 Biology and CA-4948
IRAK4 Biology and CA-4948
Slide 6: IRAK4 Biology and CA-4948
IRAK4 Biology and CA-4948 IRAK4 is a novel and important target across multiple heme malignancies IRAK4 in AML/MDS IRAK4 in B Cell Cancers Spliceosome mutation drives overexpression of IRAK4-L TLR Pathway is dependent upon IRAK4 for function (which causes constitutive activation of the myddosome) (t
Slide 7: CA-4948 Targeted Design
CA-4948 Targeted Design In Nov 2020, the NCI selected CA-4948, Curis’s CA-4948 is the most advanced IRAK4 inhibitor in clinical development for cancer first-in-class IRAK4 inhibitor, and entered into an agreement (“CRADA”) with Curis to conduct both clinical and non-clinical CA-4948 inhibits IRAK4 C
Slide 8: CA-4948 PK/PD
CA-4948 PK/PD Attractive PK profile supports BID dosing and high target suppression Attractive PK Profile High Target Suppression • Half-life of ~6 hours Trough • Exposure at RP2D correlates with 98% inhibition Exposure Dose Inhibition • Supports BID dosing regimen 2.5μM 200mg 97% 4.1μM 300mg 98% 5.
Slide 9: Preclinical Data
CA-4948 Preclinical Data Clear anti-cancer activity suggests broad potential across heme malignancies AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Monotherapy & Combination p<0.05 100 vehicle Vehicle Mean Tumor Volume (mm3) ± SEM 1200 Relative Cell Growth % p<0.05 50 p<0.05 Ibrutinib CA-49
Slide 10: CA-4948 Clinical Plan
CA-4948 Clinical Plan Planned clinical studies for AML/MDS and B cell cancers AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Monotherapy & Combination Monotherapy No monotherapy studies planned Specific Subpopulations Broader Population 1) Patients with spliceosome mutation 1) R/R patients,
Slide 11: CA-4948 in AML/MDS
CA-4948 in AML/MDS
Slide 12: CA-4948 in AML/MDS
CA-4948 in AML/MDS Clinical studies designed to leverage the role of IRAK4/FLT3 in AML/MDS % of Patient Disease Driver Population IRAK4-L > 50%1 Rationale for Monotherapy FLT3 25-30%2 • IRAK4 / FLT3 is the largest targeted market in AML/MDS1,2 TET2 10-20%3 • Spliceosome mutation is a leading cause o
Slide 13: CA-4948 in AML/MDS: Study design and patient characteristics
CA-4948 in AML/MDS Study design and patient characteristics >90% of patients enrolled had intermediate or worse cytogenetic risk Phase 1/2 Study Baseline Patient Characteristics Patients (n=22) • Open-label, single arm Female n (%) : Male n (%) 5 (23) : 17 (77) • Dose escalation and expansion Median
Slide 14: CA-4948 in AML/MDS: Preliminary safety data
CA-4948 in AML/MDS Preliminary safety data suggest differentiated profile Predictable and manageable safety profile • MTD not exceeded until 500mg BID • No dose-limiting toxicities related to myelosuppression • No overlap in dose-limiting toxicities with azacitidine and venetoclax, which are planned
Slide 15: Preliminary Clinical Data: Specific Population in Monotherapy
Preliminary Clinical Data: Specific Population in Monotherapy Clear efficacy highlights potential for rapid regulatory path in spliceosome and FLT3 Patients with Patient with Spliceosome Mutation FLT3 Mutation DNA Sequencing indicates disease modification • 4 of 4 evaluable patients w/ targeted muta
Slide 16: Preliminary Clinical Data: Broader Population in Combination
Preliminary Clinical Data: Broader Population in Combination Efficacy supports differentiated profile even in patients without spliceosome/FLT3 mutation Unselected Patients Marrow Blast Reduction Heme Improvement deepened after several cycles indicates clinical benefit • 9 of 11 evaluable patients w
Slide 17: Multiple regulatory paths in AML/MDS
CA-4948 in AML/MDS Multiple regulatory paths based on clear biologic activity and durable responses • Preliminary clinical data show clear biologic activity with Next Steps in Expansion deepening, durable responses • Monotherapy: Spliceosome mutation o In population targeted for monotherapy, • Monot
Slide 18: CA-4948 in B Cell Cancers
CA-4948 in B Cell Cancers
Slide 19: B Cell Cancers: Phase 1/2 study design and patient characteristics
CA-4948 in B Cell Cancers Monotherapy Phase 1/2 study design and patient characteristics Heavily pre-treated population Study Objectives Baseline Patient Characteristics Patients (n=31) 1ᵒ: Determine maximum tolerated dose Female n (%) : Male n (%) 26 (84) : 5 (16) Determine recommended Phase 2 dose
Slide 20: Two potential biomarkers may increase probability of success
CA-4948 in B Cell Cancers Two potential biomarkers may increase probability of success NF-κB phospho-p50 positive expression of p-p50 indicates the NF-κB complex is active BCR Pathway TLR Pathway Baseline testing may support future patient selection B cell TLR1 TLR2 Patient Best Patient Best TLR4 TL
Slide 21: Promising preliminary safety data
CA-4948 in B Cell Cancers Promising preliminary safety data 200 mg BID 300 mg BID 400 mg BID All (n=5); (%) (n=6); (%) (n=8); (%) (n=30); (%) Adverse Reaction Predictable and manageable safety profile All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades Diarrhea 20 0 33
Slide 22: Preliminary clinical data: clear reduction in tumor burden
CA-4948 in B Cell Cancers Preliminary clinical data: clear reduction in tumor burden Change in Tumor Burden for 13 Evaluable Patients Dose Response Observed in WM Patient (200mg BID+) (50mg - 300mg BID) 50% Clear Single Agent Anti-Cancer Activity at RP2D Clear Single Agent Anti-Cancer Activity • Tum
Slide 23: Preliminary clinical data: strong durability profile
CA-4948 in B Cell Cancers Preliminary clinical data: strong durability profile Patients Dosed at Recommended Ph2 Dose (300mg BID) Strong Durability Profile at RP2D Patients have remained on therapy 1-2 years dotted line indicates ongoing treatment Data cut-off: 23Nov2020 Days on Study 23
Slide 24: CA-4948 combined with BTKi
CA-4948 in B Cell Cancers CA-4948 is the ideal candidate to combine with BTKi to maximize downregulation of NF-κB Next Steps in Expansion • Patients are treated with BTKi because downregulating • BTKi naïve, Marginal Zone Lymphoma (MZL) NF-κB activity provides benefit in B Cell Cancers • BTKi naïve,
Slide 25: VISTA Biology and CI-8993
VISTA Biology and CI-8993
Slide 26: VISTA Biology
VISTA Biology VISTA is an important checkpoint regulator target across multiple malignancies • CTLA-4, PD-1, and VISTA are the three main players in controlling checkpoint blockade • VISTA controls early T cell activation events • Blockade of VISTA will allow for an expanded T cell response against
Slide 27: Role of VISTA in immune suppression in the tumor microenvironment
VISTA Biology Role of VISTA in immune suppression in the tumor microenvironment (TME) Blocking PD-1 VISTA Blocking VISTA activates T cells re-suppresses T cells1 re-activates T cells2 ❶ ❷ ❸ ❹ Normal Immune Suppression Temporary Immune Activation VISTA-mediated Immune Suppression Alleviation of Immun
Slide 28: CI-8993 Preclinical Data
CI-8993 Preclinical Data Clear anti-cancer activity suggest potential transformation of immune-oncology treatment Monotherapy Combination Therapy Anti-VISTA inhibited tumor growth Anti-VISTA inhibited xenograft growth in B16ova melanoma model1 in checkpoint resistant CT26 model2 Control n=14 100% Da
Slide 29: CI-8993 Clinical Plan
CI-8993 Clinical Plan Ongoing clinical study to determine safety Patient Population • Patients with advanced refractory solid tumors Curis Design for Ph1 Dose Escalation Study (includes mesothelioma, melanoma, NSCLC, TNBC) Treatment 0.15mg/kg Level 2 Level 3 Higher Doses Continue dose escalation • B
Slide 30: CI-8993 in Solid Tumors
CI-8993 in Solid Tumors CI-8993 has potential to be the leading anti-VISTA therapeutic • VISTA’s role in enforcing T cell quiescence limits the Next Steps in Dose Escalation effectiveness of other immune checkpoint therapies • Confirm that CI-8993 can be administered safely (that CRS can be managed)
Slide 31: Corporate Overview
Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $161M as of June 30, 2021; cash runway into 2024 CA-4948: first-in-class inhi
Slide 32: Committed, Experienced Leadership Team
Curis Committed, Experienced Leadership Team Rachel Blasbalg James Dentzer Christine Guertin Robert Martell Head, Human Resources President & CEO Head, Regulatory Head, R&D Mark Noel Reinhard von Roemeling Raul Soikes Nancy Soohoo William Steinkrauss Head, Intellectual Property Head, Clinical Develo
Slide 33: End of Corporate Presentation
End of Corporate Presentation NASDAQ: CRIS